These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25200111)

  • 21. Pathophysiology and Symptomatology of Drooling in Parkinson's Disease.
    Polychronis S; Nasios G; Dardiotis E; Messinis L; Pagano G
    Healthcare (Basel); 2022 Mar; 10(3):. PubMed ID: 35326994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings.
    Schirinzi T; Imbriani P; D'Elia A; Di Lazzaro G; Mercuri NB; Pisani A
    Clin Neurol Neurosurg; 2017 May; 156():63-65. PubMed ID: 28342306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin A as treatment for drooling saliva in PD.
    Pal PK; Calne DB; Calne S; Tsui JK
    Neurology; 2000 Jan; 54(1):244-7. PubMed ID: 10636161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sialorrhea in Parkinson's disease: a review.
    Chou KL; Evatt M; Hinson V; Kompoliti K
    Mov Disord; 2007 Dec; 22(16):2306-13. PubMed ID: 17659637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is drooling secondary to a swallowing disorder in patients with Parkinson's disease?
    Nóbrega AC; Rodrigues B; Torres AC; Scarpel RD; Neves CA; Melo A
    Parkinsonism Relat Disord; 2008; 14(3):243-5. PubMed ID: 17892967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathophysiology of diurnal drooling in Parkinson's disease.
    Kalf JG; Munneke M; van den Engel-Hoek L; de Swart BJ; Borm GF; Bloem BR; Zwarts MJ
    Mov Disord; 2011 Aug; 26(9):1670-6. PubMed ID: 21484876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of cognitive dysfunction on drooling in Parkinson's disease.
    Rana AQ; Khondker S; Kabir A; Owalia A; Khondker S; Emre M
    Eur Neurol; 2013; 70(1-2):42-5. PubMed ID: 23711510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort.
    Rascol O; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Fabbri M; Meissner WG; Rachdi A; Tison F; Perez-Lloret S;
    J Neural Transm (Vienna); 2020 Dec; 127(12):1607-1617. PubMed ID: 32880023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diurnal and nocturnal drooling in Parkinson's disease.
    Kalf JG; Bloem BR; Munneke M
    J Neurol; 2012 Jan; 259(1):119-23. PubMed ID: 21698387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drooling, Swallowing Difficulties and Health Related Quality of Life in Parkinson's Disease Patients.
    Arboleda-Montealegre GY; Cano-de-la-Cuerda R; Fernández-de-Las-Peñas C; Sanchez-Camarero C; Ortega-Santiago R
    Int J Environ Res Public Health; 2021 Jul; 18(15):. PubMed ID: 34360429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diurnal drooling in Chinese patients with Parkinson's disease.
    Ou R; Guo X; Wei Q; Cao B; Yang J; Song W; Chen K; Zhao B; Chen X; Shang H
    J Neurol Sci; 2015; 353(1-2):74-8. PubMed ID: 25896289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SIALORRHEA AND XEROSTOMIA IN PARKINSON'S DISEASE PATIENTS.
    Špiljak B; Lisak M; Pašić H; Trkanjec Z; Lovrenčić Huzjan A; Bašić Kes V
    Acta Clin Croat; 2022 Aug; 61(2):320-326. PubMed ID: 36818932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sialorrhoea and drooling in patients with Parkinson's disease: epidemiology and management.
    Merello M
    Drugs Aging; 2008; 25(12):1007-19. PubMed ID: 19021300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea.
    Steinlechner S; Klein C; Moser A; Lencer R; Hagenah J
    Psychopharmacology (Berl); 2010 Jan; 207(4):593-7. PubMed ID: 19823807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin for treatment of parkinsonian sialorrhea.
    Friedman A; Potulska A
    Neurol Neurochir Pol; 2001; 35 Suppl 3():23-7. PubMed ID: 12001650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sialorrhea: a management challenge.
    Hockstein NG; Samadi DS; Gendron K; Handler SD
    Am Fam Physician; 2004 Jun; 69(11):2628-34. PubMed ID: 15202698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A.
    Tiigimäe-Saar J; Tamme T; Rosenthal M; Kadastik-Eerme L; Taba P
    Neurol Sci; 2018 May; 39(5):871-877. PubMed ID: 29460161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease.
    Evatt ML; Chaudhuri KR; Chou KL; Cubo E; Hinson V; Kompoliti K; Yang C; Poewe W; Rascol O; Sampaio C; Stebbins GT; Goetz CG
    Mov Disord; 2009 Apr; 24(5):635-46. PubMed ID: 19205066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease.
    Guidubaldi A; Fasano A; Ialongo T; Piano C; Pompili M; Mascianà R; Siciliani L; Sabatelli M; Bentivoglio AR
    Mov Disord; 2011 Feb; 26(2):313-9. PubMed ID: 21259343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy.
    Savarese R; Diamond M; Elovic E; Millis SR
    Am J Phys Med Rehabil; 2004 Apr; 83(4):304-11; quiz 312-4, 336. PubMed ID: 15024333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.